eribulin sold brand name halaven anticancer medication used treat breast cancer common side effects include fatigue nausea hair loss alopecia constipation certain nerve damage causing weakness numbness hands feet peripheral neuropathy abdominal pain fever eribulin may also cause low levels infectionfighting white blood cells neutropenia decreased levels potassium eribulin approved medical use european union march indicated treatment mesylate salt approved us food drug administration fda november indication treat people metastatic breast cancer received least two prior chemotherapy regimens latestage disease including anthracycline taxanebased approved health canada december indication treatment people metastatic breast cancer previously received least two chemotherapeutic regimens treatment metastatic metastatic breast cancer impacts people us due small patient population eisai able file new drug application nda orphan rare disease january us food drug administration fda approved eribulin treatment inoperable liposarcoma people received prior chemotherapy contained anthracycline phase iii trial reported eribulin median overall survival participants liposarcoma months compared months participants treated serious side effects may include anaemia decrease white blood cell count increase risk serious infections could lead death hair loss cancerrelated fatigue numbness tingling burning hands feet neuropathy harm developing fetus well changes heartbeat qtc prolongation may also lead eribulin fully synthetic macrocyclic ketone analogue marine natural product halichondrin parent molecule naturally occurring potent mitotic inhibitor unique mechanism action parent molecule originally found sponge halichondria eribulin mechanistically unique inhibitor microtubule binding predominantly small number high affinity sites plus ends existing eribulin cytotoxic noncytotoxic mechanisms action cytotoxic effects related antimitotic activities wherein apoptosis cancer cells induced following prolonged irreversible mitotic addition cytotoxic antimitoticbased mechanisms preclinical studies human breast cancer models shown eribulin also exerts complex effects biology surviving cancer cells residual tumors appear unrelated antimitotic effects nonmitotic mechanisms include vascular remodeling leads increased tumor perfusion mitigation tumor hypoxia phenotypic changes consistent reversal epithelialmesenchymal transition emt decreased capacity migration invasion leading reduced metastatic capacity measured preclinical experimental metastasis studies eribulin treatment leiomyosarcoma liposarcoma cells leads increased expression smooth muscle adipocyte differentiation antigens taxaneresistant cancers often unresponsive eribulin recent study found resistance due expression multidrug resistance protein fluorescently labeled eribulin used study pharmacokinetics pharmacodynamics single cell level synthesis eribulin first new synthetic route drug published eribulin investigated use variety solid tumors including breast cancer nonsmall cell lung cancer prostate cancer brain cancer cervical cancer urothelial cancer melanoma solitary fibrous tumors various two newwhen eribulin based products research development phase liposomal formulation antibody drug combination therapy treatment solid tumors liposomal formulation eribulin liposomal currentlywhen phase clinical preliminary vivo experiments show decrease cmax longer halflife liposomal drug antibody eribulin combination therapy joint venture eisai merck clinical trials combine eribulin pembrolizumab inhibitor treatment breast cancer advanced currentlywhen five active patents united states associated halaven drug application first one expired june last one expires january httpsenwikipediaorgwikieribulin